Mycophenolate mofetil Completed Phase 3 Trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Secondary Myelodysplastic Syndromes / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Previously Treated Myelodysplastic Syndromes / Adult Acute Myeloid Leukemia in Remission / Myelodysplastic Syndrome With Isolated Del(5q) / Recurrent Childhood Acute Myeloid Leukemia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Acute Myeloid Leukemia/Transient Myeloproliferative Disorder / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Childhood Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / De Novo Myelodysplastic Syndromes / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Childhood Myelodysplastic Syndromes Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00322101Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia